港股医药IPO狂飙 上半年募资金额达156亿港元

Core Insights - In the first half of the year, 10 biopharmaceutical companies successfully listed on the Hong Kong Stock Exchange, compared to only 12 for the entire previous year [1] - The biopharmaceutical sector led the IPO activity with 6 companies, while 4 companies from the medical devices and services sector followed, making them the top two industries for IPOs in the first half of the year [1] - As of the beginning of 2025, 39 healthcare companies are in line for listing on the Hong Kong Stock Exchange [1] Industry Performance - In the first quarter of this year, there were 118 active applications for listings on the Hong Kong main board, representing a significant year-on-year increase, with the medical and pharmaceutical sectors accounting for 26% of these applications [1] - The biopharmaceutical sector raised a total of 15.6 billion HKD in the first half of the year, making it the second-highest fundraising sector for IPOs during this period, significantly above the average level of the past three years [1] - Looking ahead to the second half of 2025, the momentum for companies to pursue IPOs in Hong Kong remains strong, with over 40 biopharmaceutical companies waiting to go public [1]